NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has ...
To test the accuracy of the Octet ® assay, Fc-fusion protein was spiked into CCM and HCP matrices at known concentrations in ...
Tectonic Therapeutic (TECX) recently announced positive interim results from its phase 1b study using Fc-fusion protein TX45 for the treatment of patients with Group 2 pulmonary Hypertension in Heart ...
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly dosing ...
Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect® Fc Fusion, a novel assay designed to ...
Outcomes of continuing neoadjuvant-intent immunotherapy for advanced, resectable cutaneous squamous cell carcinoma post-operatively. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results